Charles Schwab Investment Management Inc Celldex Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 553,081 shares of CLDX stock, worth $15.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

553,081

Previous 535,844 3.22%

Holding current value

$15.3 Million

Previous $9.73 Million 15.73%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$15.13 - $21.65 $260,795 - $373,181	17,237 Added 3.22%	553,081 $11.3 Million
Q1 2025 Sep 15, 2025	SELL	$18.15 - $27.6 $312,851 - $475,741	-17,237 Reduced 3.12%	535,844 $9.73 Million
Q1 2025 May 09, 2025	SELL	$18.15 - $27.6 $154,020 - $234,213	-8,486 Reduced 1.56%	535,844 $9.73 Million
Q4 2024 Feb 06, 2025	BUY	$23.31 - $32.4 $127,598 - $177,357	5,474 Added 1.02%	544,330 $13.8 Million
Q3 2024 Nov 12, 2024	BUY	$32.06 - $44.56 $269,720 - $374,883	8,413 Added 1.59%	538,856 $18.3 Million
Q2 2024 Aug 12, 2024	BUY	$32.76 - $42.56 $1.02 Million - $1.33 Million	31,222 Added 6.25%	530,443 $19.6 Million
Q1 2024 May 08, 2024	BUY	$35.22 - $51.88 $3.16 Million - $4.66 Million	89,830 Added 21.94%	499,221 $21 Million
Q4 2023 Feb 06, 2024	BUY	$22.61 - $40.65 $1.08 Million - $1.94 Million	47,844 Added 13.23%	409,391 $16.2 Million
Q3 2023 Nov 08, 2023	BUY	$25.45 - $37.46 $275,318 - $405,242	10,818 Added 3.08%	361,547 $9.95 Million
Q2 2023 Aug 09, 2023	BUY	$30.29 - $38.28 $121,341 - $153,349	4,006 Added 1.16%	350,729 $11.9 Million
Q1 2023 May 11, 2023	SELL	$34.78 - $47.43 $53,213 - $72,567	-1,530 Reduced 0.44%	346,723 $12.5 Million
Q4 2022 Feb 13, 2023	BUY	$27.78 - $45.38 $297,857 - $486,564	10,722 Added 3.18%	348,253 $15.5 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $158,264 - $261,938	6,972 Added 2.11%	337,531 $9.49 Million
Q2 2022 Aug 15, 2022	SELL	$20.5 - $37.33 $128,104 - $233,275	-6,249 Reduced 1.86%	330,559 $8.91 Million
Q1 2022 May 13, 2022	BUY	$27.64 - $39.32 $240,827 - $342,595	8,713 Added 2.66%	336,808 $11.5 Million
Q4 2021 Feb 11, 2022	BUY	$35.68 - $56.27 $201,199 - $317,306	5,639 Added 1.75%	328,095 $12.7 Million
Q3 2021 Nov 16, 2021	BUY	$28.95 - $55.99 $6.51 Million - $12.6 Million	224,831 Added 230.3%	322,456 $17.4 Million
Q2 2021 Aug 16, 2021	BUY	$20.71 - $35.37 $1.72 Million - $2.94 Million	83,116 Added 572.86%	97,625 $3.27 Million
Q4 2020 Feb 16, 2021	SELL	$14.99 - $22.75 $31,059 - $47,138	-2,072 Reduced 12.5%	14,509 $255,000
Q3 2020 Nov 13, 2020	BUY	$9.65 - $15.19 $160,006 - $251,865	16,581 New	16,581 $246,000

Others Institutions Holding CLDX

# of Institutions

201

Shares Held

68.3M

Call Options Held

219K

Put Options Held

238K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.29B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Celldex Therapeutics, Inc. Transaction History